3M (MMM) Q4 2024 earnings summary

Executive summary

• Completed the spin-off of the healthcare business as Solventum and settled two major legal matters, marking 2024 as a pivotal year.

• Substantially completed the largest restructuring in company history, reducing headcount by ~8,700 roles and office footprint by 25%.

• All business groups achieved positive adjusted organic growth in Q4, a first in nine quarters, with Consumer segment returning to growth.

• Launched 169 new products in 2024, up 32% year-over-year, driving growth across business groups.

• Returned $3.8 billion to shareholders in 2024 through dividends and share repurchases.

Financial highlights

• Q4 adjusted sales were $5.8 billion, with 2.1% organic growth and adjusted EPS of $1.68; full-year adjusted sales were $23.6 billion, organic growth 1.2%, and adjusted EPS $7.30, up 21% year-over-year.

• Q4 free cash flow was $1.3 billion (145% conversion); full-year free cash flow was $4.9 billion (111% conversion).

• Adjusted operating margins expanded 280 basis points to 21.4% for the year.

• Asia-Pacific led geographic growth, up 4.4%, with U.S. up 0.7% and EMEA down 1.3%.

• Q4 net income from continuing operations was $728 million, up 14.8% year-over-year; full-year $4,009 million.

Outlook and guidance

• 2025 guidance: 2%-3% organic sales growth, adjusted EPS of $7.60-$7.90 (4%-8% growth), and ~100% free cash flow conversion.

• Margin expansion of 130-190 basis points expected, driven by operational excellence and restructuring benefits.

• All business groups expected to grow low single digits, in line with or above macro trends.

• Gross share repurchases planned at $1.5 billion in 2025; capex expected at ~$1 billion.

• 2025 adjusted operating cash flow expected between $5.2 and $5.3 billion.